Orasure Technologies, Inc. · NASDAQ:OSUR
Orasure Technologies — Merger or Acquisition (December 2024)
11 slides from Orasure Technologies's merger presentation, Dec 19, 2024
Slide 1: Acquisition of Sherlock Biosciences
OraSure Technologies ACQUISITION OF SHERLOCK BIOSCIENCES DECEMBER 19, 2024 EXHIBIT 99.1
Slide 2: Forward-looking statements
© 2024 OraSure Technologies, Inc. 2 This presentation contains certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including with respect to OraSure Technologies, Inc.’s (“OraSure”) acquisition of Sherlock Biosciences, Inc. (“Sherlock”), r
Slide 3: Executive Summary
© 2024 OraSure Technologies, Inc. 3 Executive Summary • Sherlock expands OTI's portfolio with next-generation molecular diagnostics at the point-of-need (PON) • OTI gains … + Scalable platform for disposable, instrument-free Molecular self-tests with strong clinical performance + Addition of Sherloc
Slide 4: Acquisition of Sherlock aligns with OTI's mission & vision
© 2024 OraSure Technologies, Inc. 4 Acquisition of Sherlock aligns with OTI’s mission & vision Growth of precision medicine Connecting the needs of the user directly to healthcare Move to point-of-need (PON) & self-testing diagnostics OTI is Focused on Where the Future of Healthcare is Going…
Slide 5: Powering the Shift that Connects People to Healthcare Wherever They Are
© 2024 OraSure Technologies, Inc. 5 Diagnostics (Dx) Actionable point-of-need & self-testing increases access & affordability of care Best-in-class portfolio of tests in infectious disease – sexual health & respiratory … ex. HIV, HCV, Syphilis, COVID-19, Ebola, Marburg others Sample Management Sol
Slide 6: Power the Industry with Infrastructure + Innovation
© 2024 OraSure Technologies, Inc. 6 Power the Industry with Infrastructure + Innovation “OTI”
Slide 7: OTI Portfolio – Diagnostics
© 2024 OraSure Technologies, Inc. 7 OTI Portfolio – Diagnostics Sherlock accelerates our innovation pipeline with next-gen molecular platform & new test expansion OTI Diagnostics Actionable point-of need & self-testing increases affordability & access to care Broad array of infectious disease – sexu
Slide 8: Sherlock Technology Platforms
© 2024 OraSure Technologies, Inc. 8 Sherlock Disposable Self-Test (in clinical trial) Next-Gen Technologies (in development) Sherlock Technology Platforms Molecular testing to strengthen and broaden our diagnostic portfolio • Single-use, over-the-counter • Easy to use at point-of-need • Focused on S
Slide 9: Sherlock Enables Entry into Large Addressable Markets
© 2024 OraSure Technologies, Inc. 9 OTI strengths Infrastructure & commercial reach Infectious disease portfolio breadth Sexual health expertise Attractive segments CT/NG: $1.5B & growing market1 Patients desire privacy & speed for STI testing Sherlock Enables Entry into Large Addressable Markets wh
Slide 10: Investments in innovation and scale-up for launch
© 2024 OraSure Technologies, Inc. 10 Investments in innovation Scale-up for launch Advance differentiated platform & pipeline of molecular tests Growth potential Clinical trial underway Anticipate submission to FDA by end of 2025 Revenue Growth from Sherlock Powered by NT Investments
Slide 11: Sherlock Enhances Key Elements for OTI's Long-Term Success
© 2024 OraSure Technologies, Inc. 11 Sherlock Enhances Key Elements for OTI’s Long-Term Success Key Elements Sherlock Contributes Product portfolio & pipeline • CT/NG disposable Molecular self-test offers fast results, lab-like accuracy • Clinical trial for CT/NG test is on-going, OTI plans for FDA
OraSure Technologies — Merger or Acquisition (December 2024) on 6ix